Clinical trial / 2021
Adding subcutaneous semaglutide to intensive behavioral therapy and an initial low-calorie diet significantly increased weight loss over 68 weeks.
A 68-week trial randomized 611 adults with overweight or obesity to once-weekly subcutaneous semaglutide (2.4 mg) or placebo, both combined with intensive behavioral therapy and an initial 8-week low-calorie diet. At week 68, estimated mean body weight change was -16.0% with semaglutide compared to -5.7% with placebo (difference: -10.3 percentage points, P < .001). Significantly more participants in the semaglutide group achieved weight losses of at least 5% (86.6% vs 47.6%), 10% (75.3% vs 27.0%), and 15% (55.8% vs 13.2%). Gastrointestinal adverse events occurred in 82.8% of semaglutide participants versus 63.2% with placebo, causing discontinuation in 3.4% and 0%, respectively.
- Study type
- Randomized, double-blind, parallel-group trial
- Who was studied
- 611 adults without diabetes with overweight plus ≥1 comorbidity or obesity
- What was measured
- Percentage change in body weight and loss of ≥5%, ≥10%, or ≥15% of baseline weight at week 68
THE PAPER
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT, STEP 3 Investigators. JAMA, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.